See the DrugPatentWatch profile for tigecycline

Tigecycline is a broad-spectrum antibiotic that is effective against a variety of bacteria, including drug-resistant strains [1]. It is a glycylcycline antibiotic, a class of drugs that is a derivative of tetracyclines [1]. Tigecycline is effective in treating infections caused by the following bacteria:

1. Gram-positive bacteria: Tigecycline has activity against methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococci (VRE) [1]. It is also effective against other Gram-positive bacteria such as Streptococcus pneumoniae, Streptococcus pyogenes, and Staphylococcus epidermidis [1].
2. Gram-negative bacteria: Tigecycline is active against many Gram-negative bacteria, including Enterobacter species, Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii [1]. However, it has limited activity against Proteus and Providencia species [1].
3. Anaerobic bacteria: Tigecycline has activity against anaerobic bacteria, including Bacteroides fragilis, Clostridium perfringens, and Peptostreptococcus species [1].

Tigecycline is used to treat complicated skin and skin structure infections, complicated intra-abdominal infections, and community-acquired bacterial pneumonia [1]. It is also used as a last-resort treatment for drug-resistant bacterial infections [1].

In summary, tigecycline is a broad-spectrum antibiotic that is effective against a range of Gram-positive, Gram-negative, and anaerobic bacteria, including drug-resistant strains such as MRSA and VRE.

Sources:

[1] DrugPatentWatch.com. (n.d.). Tigecycline. Retrieved from <https://www.drugpatentwatch.com/bulk-antibiotics/tigecycline.html>